85 related articles for article (PubMed ID: 11229339)
1. The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Ali-Osman F; Srivenugopal K; Sawaya R
N Engl J Med; 2001 Mar; 344(9):687; author reply 687-8. PubMed ID: 11229339
[No Abstract] [Full Text] [Related]
2. The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Quinn DI
N Engl J Med; 2001 Mar; 344(9):686; author reply 687-8. PubMed ID: 11229338
[No Abstract] [Full Text] [Related]
3. The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Buckner JC; Moynihan TJ
N Engl J Med; 2001 Mar; 344(9):686; author reply 687-8. PubMed ID: 11229337
[No Abstract] [Full Text] [Related]
4. The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Schlegel U
N Engl J Med; 2001 Mar; 344(9):686-7; author reply 687-8. PubMed ID: 11229336
[No Abstract] [Full Text] [Related]
5. Pharmacogenomics--teaching old drugs new tricks.
Weinstein JN
N Engl J Med; 2000 Nov; 343(19):1408-9. PubMed ID: 11070107
[No Abstract] [Full Text] [Related]
6. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Esteller M; Garcia-Foncillas J; Andion E; Goodman SN; Hidalgo OF; Vanaclocha V; Baylin SB; Herman JG
N Engl J Med; 2000 Nov; 343(19):1350-4. PubMed ID: 11070098
[TBL] [Abstract][Full Text] [Related]
7. The correlation between promoter methylation status and the expression level of O6-methylguanine-DNA methyltransferase in recurrent glioma.
Suzuki T; Nakada M; Yoshida Y; Nambu E; Furuyama N; Kita D; Hayashi Y; Hayashi Y; Hamada J
Jpn J Clin Oncol; 2011 Feb; 41(2):190-6. PubMed ID: 21148162
[TBL] [Abstract][Full Text] [Related]
8. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
Sasai K; Nodagashira M; Nishihara H; Aoyanagi E; Wang L; Katoh M; Murata J; Ozaki Y; Ito T; Fujimoto S; Kaneko S; Nagashima K; Tanaka S
Am J Surg Pathol; 2008 Aug; 32(8):1220-7. PubMed ID: 18580490
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
Brell M; Tortosa A; Verger E; Gil JM; Viñolas N; Villá S; Acebes JJ; Caral L; Pujol T; Ferrer I; Ribalta T; Graus F
Clin Cancer Res; 2005 Jul; 11(14):5167-74. PubMed ID: 16033832
[TBL] [Abstract][Full Text] [Related]
10. Alterations in S-adenosylhomocysteine metabolism decrease O6-methylguanine DNA methyltransferase gene expression without affecting promoter methylation.
Hermes M; Geisler H; Osswald H; Riehle R; Kloor D
Biochem Pharmacol; 2008 Jun; 75(11):2100-11. PubMed ID: 18395186
[TBL] [Abstract][Full Text] [Related]
11. Targeted modulation of MGMT: clinical implications.
Liu L; Gerson SL
Clin Cancer Res; 2006 Jan; 12(2):328-31. PubMed ID: 16428468
[TBL] [Abstract][Full Text] [Related]
12. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer.
Esteller M; Herman JG
Oncogene; 2004 Jan; 23(1):1-8. PubMed ID: 14712205
[TBL] [Abstract][Full Text] [Related]
13. O6 -methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: a review of current status.
Suri V; Jha P; Sharma MC; Sarkar C
Neurol India; 2011; 59(2):229-35. PubMed ID: 21483124
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
15. O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma.
Zuo C; Ai L; Ratliff P; Suen JY; Hanna E; Brent TP; Fan CY
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):967-75. PubMed ID: 15184253
[TBL] [Abstract][Full Text] [Related]
16. DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors.
Yin D; Xie D; Hofmann WK; Zhang W; Asotra K; Wong R; Black KL; Koeffler HP
Mol Carcinog; 2003 Jan; 36(1):23-31. PubMed ID: 12503076
[TBL] [Abstract][Full Text] [Related]
17. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.
Pollack IF; Hamilton RL; Sobol RW; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL
J Clin Oncol; 2006 Jul; 24(21):3431-7. PubMed ID: 16849758
[TBL] [Abstract][Full Text] [Related]
18. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents.
Srivenugopal KS; Shou J; Mullapudi SR; Lang FF; Rao JS; Ali-Osman F
Clin Cancer Res; 2001 May; 7(5):1398-409. PubMed ID: 11350911
[TBL] [Abstract][Full Text] [Related]
19. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.
Eoli M; Menghi F; Bruzzone MG; De Simone T; Valletta L; Pollo B; Bissola L; Silvani A; Bianchessi D; D'Incerti L; Filippini G; Broggi G; Boiardi A; Finocchiaro G
Clin Cancer Res; 2007 May; 13(9):2606-13. PubMed ID: 17473190
[TBL] [Abstract][Full Text] [Related]
20. Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase.
Lavon I; Fuchs D; Zrihan D; Efroni G; Zelikovitch B; Fellig Y; Siegal T
Cancer Res; 2007 Sep; 67(18):8952-9. PubMed ID: 17875738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
